Investor Update Webinar Presentation

• Mildura facility is world-class with automation and sophisticated continuous cropping system
• Breeding program focused on patient desirables and importing high-quality genetics
• Diverse product range including own-brand Botanitech and contract services at cGMP facility

Cann Group Limited (ASX: CAN) is pleased to provide an investor presentation on the company's strategic growth plans and investment opportunity, as well as further information on the Non-renounceable Entitlement Offer that opened on 15 October 2024. The presentation will be delivered by Cann CEO & Managing Director, Jenni Pilcher, and Head of Commercial, Carlyn Villani, at Cann's investor update webinar on Thursday, 17 October 2024. Cann Group is the first Australian company to have been issued with a Cannabis Research Licence and Cannabis Cultivation Licence by the Australian Government's Office of Drug Control in 2017. The company's flagship Mildura facility, which was fully commissioned in 2022, is world-class with a level of automation and sophistication of its continuous cropping system that sets Cann apart from its competitors. Cann's breeding program focuses on key 'patient desirables' such as flavor, aroma, bud aesthetics, and target cannabinoid potency, while also importing high-quality genetics from leading breeders in North America. The company's product range includes its own-brand Botanitech, as well as white-label dried flower and oils, and Satipharm's CBD, THC, and balanced capsules. Cann also offers contract growing, packing, and laboratory services at its cGMP facility. The company is well-positioned to seize the growing medicinal cannabis market opportunity in Australia, with its expertise, established customer base, and cutting-edge R&D program.

Cann Group is targeting 10 tonnes of dried flower production per annum by FY2027, which is expected to deliver strong revenue growth and profitability at an average selling price of $3.45 per gram (FY2024). The company is progressing towards EBITDA profitability in FY2025 and cash flow positive in FY2026.

Cann Group is focused on increasing the scale and quality of its production, expanding its product portfolio to meet market demands, and driving revenue growth through its extensive R&D breeding program and the expansion of its Mildura facility. The company is on a path towards EBITDA profitability and cash flow positive operations.